The sGC-stimulator Riociguat for the treatment of Raynaud's phenomenon: A single-dose, double-blind, randomized, placebo-controlled cross-over study (DIGIT)

Documenti analoghi

• Riociguat for pulmonary arterial hypertension associated with congenital heart disease
  di: Rosenkranz, Stephan, et al.
  Pubblicazione: (2015)
• The clinical development of sGC modulators, riociguat and vericiguat
  di: Misselwitz, Frank
  Pubblicazione: (2015)
• Platelet inhibitory effects of the NO independent sGC stimulator riociguat (Bay 63-2561)
  di: Reiss, Cora, et al.
  Pubblicazione: (2013)
• Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies
  di: Stephan, Rosenkranz, et al.
  Pubblicazione: (2015)
• The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood
  di: Reiss, C., et al.
  Pubblicazione: (2015)